Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 60.1% in April

Bio-Path Holdings, Inc. (NASDAQ:BPTHGet Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 96,200 shares, a growth of 60.1% from the March 31st total of 60,100 shares. Based on an average trading volume of 65,100 shares, the days-to-cover ratio is currently 1.5 days.

NASDAQ:BPTH opened at $2.93 on Friday. The business’s fifty day moving average price is $3.43 and its 200 day moving average price is $3.96. Bio-Path has a 12 month low of $2.73 and a 12 month high of $8.62.

Bio-Path (NASDAQ:BPTHGet Rating) last posted its earnings results on Friday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.27). Analysts predict that Bio-Path will post -1.76 EPS for the current fiscal year.

A number of analysts have recently weighed in on BPTH shares. StockNews.com started coverage on Bio-Path in a research report on Wednesday. They set a “sell” rating on the stock. Zacks Investment Research lowered Bio-Path from a “buy” rating to a “hold” rating in a research report on Monday, January 17th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bailard Inc. acquired a new position in Bio-Path in the fourth quarter valued at $126,000. Morgan Stanley boosted its stake in Bio-Path by 1,525.4% in the third quarter. Morgan Stanley now owns 21,130 shares of the company’s stock valued at $108,000 after acquiring an additional 19,830 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in Bio-Path by 23.1% in the second quarter. Citadel Advisors LLC now owns 25,356 shares of the company’s stock valued at $169,000 after acquiring an additional 4,765 shares in the last quarter. Institutional investors own 6.06% of the company’s stock.

Bio-Path Company Profile (Get Rating)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Stories

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.